C4 Therapeutics
CCCC
113 hedge funds and large institutions have $298M invested in C4 Therapeutics in 2022 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 39 increasing their positions, 34 reducing their positions, and 36 closing their positions.
7,038% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $32K
15% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 34
4.24% more ownership
Funds ownership: 76.58% → 80.81% (+4.2%)
10% less funds holding
Funds holding: 125 → 113 (-12)
28% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 36
67% less capital invested
Capital invested by funds: $905M → $298M (-$607M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$36.3M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$34.6M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.68M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.02M |
| 5 |
Walleye Capital
New York
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$15.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$13.3M |
| 3 |
RI
RTW Investments
New York
|
-$12.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.2M |
| 5 |
CC
Commodore Capital
New York
|
-$11.7M |
CCCC Hedge Fund Activity: Q2 2022 in Review
113 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q2 2022, worth a combined $298M — down 67% from $905M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of CCCC and 26 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 39 added.
The largest buyer was Wasatch Advisors, adding an estimated $36.3M. The largest seller was Pura Vida Investments, exiting entirely with an estimated $15.2M sold.
- 113 institutional investors held C4 Therapeutics (CCCC) as of Q2 2022, down from 125 in Q1 2022.
- Funds reported $298M of C4 Therapeutics stock for Q2 2022, down 67% quarter-over-quarter.
- 26 funds opened new C4 Therapeutics positions in Q2 2022 and 36 closed out, a net change of -10 holders.
- The largest C4 Therapeutics buyer in Q2 2022 was Wasatch Advisors, an estimated $36.3M added.
- The largest C4 Therapeutics seller in Q2 2022 was Pura Vida Investments, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2022.